ドライアイ症候群：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 21
3.1.3 Classification 23
3.1.4 Prognosis 23
3.1.5 Quality of Life 24
3.2 Symptoms 24
4 Epidemiology 26
4.1 Risk Factors and Comorbidities 26
4.1.1 Risk of dry eye syndrome increases 35% each decade after age 40 27
4.1.2 Women are twice as likely to have dry eye syndrome as men 27
4.1.3 Use of certain medications may increase the risk of developing dry eye syndrome 28
4.1.4 Diets rich in omega-3 fatty acids help prevent dry eye syndrome 29
4.1.5 Certain environmental conditions can double the risk of dry eye syndrome 29
4.2 Global Trends 29
4.2.1 US 30
4.2.2 5EU 30
4.2.3 Asia 30
4.3 Forecast Methodology 31
4.3.1 Sources Used 32
4.3.2 Forecast Assumptions and Methods 34
4.3.3 Sources Not Used 36
4.4 Epidemiology Forecast (2012-2022) 37
4.4.1 Prevalent Cases of Dry Eye Syndrome 37
4.4.2 Age-Specific Prevalent Cases 39
4.4.3 Sex-Specific Prevalent Cases 42
4.4.4 Age-Standardized Prevalence of Dry Eye Syndrome 43
4.5 Discussion 45
4.5.1 Conclusions on Epidemiology Trends 45
4.5.2 Limitations of the Analysis 47
4.5.3 Strengths of the Analysis 47
5 Disease Management 48
5.1 Overview 48
5.1.1 Diagnosis Overview 48
5.1.2 Treatment Guidelines 51
5.1.3 Treatment Overview 55
5.2 US 58
5.2.1 Diagnosis 58
5.2.2 Clinical Practice 59
5.3 France 60
5.3.1 Diagnosis 60
5.3.2 Clinical Practice 61
5.4 Germany 62
5.4.1 Diagnosis 62
5.4.2 Clinical Practice 62
5.5 Italy 63
5.5.1 Diagnosis 63
5.5.2 Clinical Practice 63
5.6 Spain 64
5.6.1 Diagnosis 64
5.6.2 Clinical Practice 64
5.7 UK 65
5.7.1 Diagnosis 65
5.7.2 Clinical Practice 65
5.8 Japan 66
5.8.1 Diagnosis 66
5.8.2 Clinical Practice 66
5.9 China 68
5.9.1 Diagnosis 68
5.9.2 Clinical Practice 68
5.10 India 69
5.10.1 Diagnosis 69
5.10.2 Clinical Practice 69
6 Competitive Assessment 71
6.1 Overview 71
6.2 Strategic Competitor Assessment 71
6.3 Product Profiles – Major Brands 73
6.3.1 Restasis (cyclosporine 0.05% ophthalmic emulsion) 73
6.3.2 Diquas (diquafosol tetrasodium) 78
6.3.3 Mucosta (rebamipide 2% ophthalmic suspension) 82
6.3.4 Additional Therapies 85
7 Opportunity and Unmet Need 89
7.1 Overview 89
7.2 Diagnostic tests are not specific enough to identify subgroups of patients 90
7.3 Frequent dosing and side effects limit compliance 91
7.4 Lack of physician and patient awareness 92
7.5 Trial design may be a factor in so few drugs being approved 93
7.6 Unmet Needs Gap Analysis 94
7.7 Comprehensive method for measuring dry eye signs and severity levels 95
7.8 Increase treatment rates among milder forms of the disease 96
8 Pipeline Assessment 97
8.1 Overview 97
8.2 Clinical Trial Mapping 98
8.2.1 Clinical Trials by Country 98
8.2.2 Clinical Trials by Phase and Trial Status 99
8.3 Promising drugs in clinical development 100
8.3.1 Lifitegrast 101
8.3.2 CF-101 105
8.3.3 Cyclokat 109
8.3.4 EGP-437 114
8.3.5 RX-10045 118
8.3.6 MIM-D3 122
9 Current and Future Players 126
9.1 Overview 126
9.2 Trends in Corporate Strategy 128
9.3 Company Profiles 129
9.3.1 Allergan 129
9.3.2 Alcon (a wholly-owned subsidiary of Novartis AG) 131
9.3.3 Santen Pharmaceutical 133
9.3.4 Shire/SARcode Bioscience 137
9.3.5 Otsuka Holdings 139
9.3.6 Can-Fite Biopharma 141
9.3.7 Eyegate Pharma 142
10 Market Outlook 144
10.1 Global Markets 144
10.1.1 Forecast 144
10.1.2 Drivers and Barriers – Global Issues 146
10.2 United States 149
10.2.1 Forecast 149
10.2.2 Key Events 152
10.2.3 Drivers and Barriers 152
10.3 France 155
10.3.1 Forecast 155
10.3.2 Key Events 157
10.3.3 Drivers and Barriers 157
10.4 Germany 159
10.4.1 Forecast 159
10.4.2 Key Events 161
10.4.3 Drivers and Barriers 161
10.5 Italy 163
10.5.1 Forecast 163
10.5.2 Key Events 165
10.5.3 Drivers and Barriers 165
10.6 Spain 167
10.6.1 Forecast 167
10.6.2 Key Events 169
10.6.3 Drivers and Barriers 169
10.7 United Kingdom 170
10.7.1 Forecast 170
10.7.2 Key Events 172
10.7.3 Drivers and Barriers 172
10.8 Japan 174
10.8.1 Forecast 174
10.8.2 Key Events 176
10.8.3 Drivers and Barriers 176
10.9 China 178
10.9.1 Forecast 178
10.9.2 Key Events 180
10.9.3 Drivers and Barriers 180
10.10 India 182
10.10.1 Forecast 182
10.10.2 Key Events 183
10.10.3 Drivers and Barriers 184
11 Appendix 185
11.1 Bibliography 185
11.2 Abbreviations 192
11.3 Methodology 194
11.4 Forecasting Methodology 194
11.4.1 Diagnosed DES patients 194
11.4.2 Percent Drug-treated Patients 195
11.4.3 Drugs Included in Each Therapeutic Class 195
11.4.4 Launch and Patent Expiry Dates 195
11.4.5 General Pricing Assumptions 196
11.4.6 Individual Drug Assumptions 197
11.4.7 Generic Erosion 201
11.5 Physicians and Specialists Included in this Study 202
11.6 About the Authors 203
11.6.1 Author 203
11.6.2 Epidemiologist 204
11.6.3 Reviewers 205
11.6.4 Global Director of Epidemiology and Clinical Trials Analysis 206
11.6.5 Global Head of Healthcare 207
11.7 About GlobalData 208
11.8 Contact Us 208
11.9 Disclaimer 208